Skip to main content
Nobuaki Matsubara on Muck Rack

Nobuaki Matsubara

As seen in: Wiley Online Library, Annals of Oncology, The Lancet, European Urology, UroToday, Clinical Genitourinary Cancer
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Nobuaki

Contact Nobuaki, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer.

|
By Neeraj Agarwal, Nobuaki Matsubara, Arun A. Azad
| UroToday Verified
A previous trial involving patients with metastatic prostate cancer that was resistant to androgen pathway modulation (formerly referred to as castration-resistant) showed that adding talazoparib to enzalutamide significantly improved imaging-based progression-free survival and overall survival, with the greatest benefit observed in the cohort with alterations in homologous recombination repair genes.
Open in Who Shared Issue with article?

First-In-Human Study: Dose Expansion of E7130 in Urothelial Carcinoma and Squamous Cell Carcinoma of the Head and Neck

|
By Nobuaki Matsubara, Ken Saijo, Yasushi Shimizu
| Wiley Online Library Verified
BOR best overall response CAF cancer-associated fibroblast CBR clinical benefit rate CI confidence interval CR complete response CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events DCE-MRI dynamic contrast-enhanced MRI DCR disease control rate DEGs differentially expressed genes DLT dose-limiting toxicity DOR duration of response ECLIA electrochemiluminescence immunoassay ECOG PS Eastern Cooperative Oncology Group performance status FDR false discovery rate GSEA...
Open in Who Shared Issue with article?

Patient-reported outcomes in TALAPRO-2 trial: addressing data integrity and comparative clinical benefit in mCRPC

|
By Nobuaki Matsubara
| cco.amegroups.org
Have a website account?Log In orRegister for exclusive website content. Home / Vol 15, No 1 (February 28, 2026) / Patient-reported outcomes in TALAPRO-2 trial: addressing data integrity and comparative clinical benefit in mCRPC PDF 1 views Full Text 1 views COI Form 3 views Session Timed Out Your session has expired. Please sign in again.
Open in Who Shared View Duplicates (12) Issue with article?
See all 15 articles